Key facts
- Comphya’s last known valuation is $80.8M (Jul 2025).
- It has raised $16.8M.
- Notable investors include Venture Kick, Ecole Polytechnique Federale de Lausanne, Verve Ventures, Zürcher Kantonalbank, Venture (Switzerland) — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Comphya
- ·The full record, as it builds
Funding rounds
No funding rounds for Comphya are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Comphya
Developer of a novel implantable device designed to treat erectile dysfunction. The company's device provides self-controlled stimulation via a wireless remote control to the cavernous nerve to restore natural function, enabling patients to have a safe and effective alternative and improve their quality of life.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Employees
- 10
- Website
- comphya.com/
- Ownership
- Privately Held (backing)
Comphya doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Comphya shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Comphya in its N-PORT filings yet. We sweep new filings monthly.